Acute myocardial infarction and pulmonary embolism in a young man with pernicious anemia-induced severe hyperhomocysteinemia
© Melhem et al; licensee BioMed Central Ltd. 2009
Received: 19 November 2008
Accepted: 13 May 2009
Published: 13 May 2009
A 27 year-old man who presented to the hospital with progressive lower extremity weakness, developed an acute ST elevation myocardial infarction on his second hospital day. Primary angioplasty to the left anterior descending coronary artery was performed. Due to persistent dyspnea, the patient underwent a diagnostic chest computed tomography which confirmed multiple small pulmonary emboli. Laboratory analysis revealed a megaloblastic anemia with a reduced vitamin B12 level and positive titers for antibodies against intrinsic factor, establishing a diagnosis of pernicious anemia. Screening for hypercoaguable markers documented an isolated severely elevated homocysteine levels (105 μmol/l). No other significant risk factors for coronary artery disease including a family history of premature atherosclerosis were identified. This case illustrates the importance of testing for hyperhomocysteinemia as part of a workup for atherothrombotic disease, especially in patients without other significant risk factors. The severity of hyperhomocysteinemia found in our patient is unusual for patients with vitamin B12 malabsorption and raises the question of whether the widely practiced folic acid fortification in the United States may mask or even worsen vitamin B12 deficiency over time, leading to more severe cases of vitamin B12 deficiency and hyperhomocysteinemia than seen in the past.
Multiple epidemiological studies have demonstrated a strong association between atherosclerotic vascular diseases and hyperhomocysteinemia [1–3]. Levels of hyperhomocysteinemia have been classified into mild-moderate (homocysteine level, 16 to 30 μmol per liter), intermediate (>31 to 100 μmol per liter), and severe (>100 μmol per liter). Meta-analysis calculated an odds ratio of 1.32 (95% confidence interval 1.19 to 1.45) for the presence of ischemic heart disease with a 5 μmol/l increase in serum homocysteine [4, 5]. The independent risk of cardiovascular events conferred by moderately elevated serum homocysteine was the rational behind the design for several recent prospective and randomized clinical trials administering folic acid and B-vitamin supplementations to lower serum homocysteine levels; all studies to-date, however, have failed to achieve improved vascular outcomes [6–10].
While mild to moderately elevated homocysteine levels are caused by a variety of factors including nutritional deficiency of vitamin cofactors involved in the homocysteine metabolism, severe elevation is generally only observed in rare cases of genetic defects in the enzymes which metabolize homocysteine. We present a young man with an acute myocardial infarction due to a thrombotic occlusion of the left anterior descending coronary artery who also developed pulmonary emboli in the setting of severe hyperhomocysteinemia secondary to pernicious anemia.
Summary of thrombophilia screening laboratory findings
Results (Normal Range)
10.6 seconds (8.9–11.7)
International Normalized Ratio (INR)
Activated Partial Thromboplastin Time
6.79 mg/l (0.97–2.12)
Protein C activity (%)
Protein S activity (%)
Antithrombin III activity
Factor V Leiden mutation
Prothrombin gene mutation
Phospholipid (Cardiolipin) AB IgG
Negative with <0.4 (norm <10.0)
Phospholipid (Cardiolipin) AB IgM
Negative with <0.4 (norm <10.0)
Phospholipid (Cardiolipin) AB IgA
Negative with <0.4 (norm <10.0)
DNA doublestranded AB IgG
Negative with <0.4 (norm <10.0)
A repeat transthoracic echocardiogram performed seven days after the myocardial infarction showed persistent anterior hypokinesis with normal left ventricular function. The right ventricular size and function were again documented to be normal. After ten days of treatment with vitamin B12 and folic acid supplements, homocysteine levels normalized to 12.9 μmol/l. His neurological symptoms gradually improved and the patient was ultimately transferred to a physical therapy rehabilitation facility with the following medical therapy: warfarin, vitamin B12 s.c. supplementation, aspirin, metoprolol, lisinopril and eplerenone.
Kilmer McCully, the first pioneer to study the role of hyperhomocysteinemia in the pathogenesis of arteriosclerosis, began by studying two children with two different forms of hereditary enzymatic defects which led to severe hyperhomocystenemia. Both these children presented with significant vascular disease at very young ages. In 1969, McCully concluded that the vascular damage in both cases was caused by an severely elevated homocysteine level and he suggested a possible similar mechanism in patients without genetic defects but who have mild to moderately elevated homocysteine levels . In the years that followed, a large number of studies supported the presence of a strong association between elevated homocysteine levels and various atherothrombotic diseases including stroke, venous thromboembolism (VTE) and ischemic cardiac disease [1–3]; a meta-analysis of clinical observational studies consistently found that a 25 percent reduction in the serum homocysteine concentration is associated with an 11 percent lower risk of ischemic heart disease (odds ratio, 0.89; 95% confidence interval, 0.83 to 0.96) and a 19 percent lower risk of stroke (odds ratio, 0.81; 95% confidence interval, 0.69 to 0.95) . Furthermore, in vitro studies and animal models of hyperhomocysteinemia have clearly shown multiple mechanisms of homocysteine induced vascular dysfunction. Inhibition of endothelial cell nitric oxide production, enhanced oxidative stress, IL-8 up-regulation leading to enhanced leukocyte recruitment, and up-regulation of tissue factor within the vasculature are among many mechanisms proposed underpinning homocysteine induced cell injury [12–15]. However, lowering mildly elevated homocysteine levels in patients with and without vascular disease using vitamin supplementation did not show a reduction in cardiovascular events in several prospective and randomized clinical studies [7–10]. Possibly harmful effects of vitamin therapy in certain settings have been suggested in some trials. For example, the folate after coronary intervention (FACIT) trial demonstrated that administration of folic acid, vitamin B12 and vitamin B6 after coronary stenting might increase the risk of in-stent restenosis and the need for target-vessel revascularization .
In contrast to those studies which included patients with mild to moderate elevations in homocysteine, our patient had a severely elevated homocysteine level. Interestingly, the etiology of the severity of hyperhomocysteinemia in this case is not exactly clear as isolated vitamin B12 deficiency due to pernicious anemia has not been reported to directly cause such unusually high homocysteine levels [17–19]. We did not identify other causes of hyperhomocysteinemia and genetic testing for the common C677T MTHFR gene mutation was negative. We realize the limitation of testing for only one gene mutation, given that a number of other genetic mutations in enzymes involved in homocysteine metabolism can contribute to an elevation in plasma homocysteine levels . However, the absence of a family history for atherothrombotic diseases together with the normalization of his homocysteine level after only ten days of parenteral vitamin B12 supplementation strongly support that indeed vitamin B12 malabsorption secondary to pernicious anemia is the underlying cause of his severe hyperhomocysteinemia. His normal folate level likely may have contributed to the severity of the homocysteine elevation by masking his megaloblastic anemia, and leading to a later presentation of a more severe neuropathy.
In fact, a recent study using data from the National Health and Nutrition Survey (NHANES) between 1999–2002 found that participants with vitamin B12 deficiency and high serum folate had increased homocysteine levels compared to participants who had the combination of vitamin B12 deficiency and low serum folate, suggesting a role of folate levels in vitamin B12's enzymatic functions . We speculate that his normal folate levels may have contributed to the delay in diagnosing pernicious anemia leading to severe hyperhomocysteinemia and the consequent development of vascular injury and hypercoaguability which presented as an acute myocardial infarction and multiple pulmonary emboli.
This case clearly demonstrates that vitamin B12 deficiency caused by pernicious anemia may lead to a severely elevated homocysteine levels that can be rapidly corrected with vitamin B12 supplements. Severe hyperhomocysteinemia can be a risk factor for endothelial damage, vascular inflammation and thrombus formation leading to pulmonary emboli and in-situ coronary artery thrombus formation. We conclude that severe hyperhomocysteinemia needs to be considered in the work-up of acute myocardial infarction not explained by atherosclerotic heart disease. Although studies have shown no preventive benefit from correcting mildly elevated homocysteine levels, severe elevation in homocysteine level should be corrected with appropriate vitamin therapy to prevent vascular complications.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Left Anterior Descending artery.
This work was supported by a grant from the Doris Duke Charitable Foundation (MAH).
- Kang S, Wong P, Malinow M: Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992, 12: 279-98. 10.1146/annurev.nu.12.070192.001431View ArticlePubMedGoogle Scholar
- Welch G, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998, 338(15):1042-50. 10.1056/NEJM199804093381507View ArticlePubMedGoogle Scholar
- Boushey CJ, Beresford SA, Omenn , Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274(13):1049-57. 10.1001/jama.274.13.1049View ArticlePubMedGoogle Scholar
- Wald D, Law M, Morris J: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325(7374):1202. 10.1136/bmj.325.7374.1202PubMed CentralView ArticlePubMedGoogle Scholar
- Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288: 2015-2022. 10.1001/jama.288.16.2015View ArticleGoogle Scholar
- Bazzano LA, Reynolds K, Holder KN, He J: Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of rendomized controlled trials. JAMA 2006, 296(22):2720-6. Erratum in: JAMA. 2007 Mar 7;297(9):952 10.1001/jama.296.22.2720View ArticlePubMedGoogle Scholar
- The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354: 1567-1577. 10.1056/NEJMoa060900View ArticleGoogle Scholar
- Toole J, Malinow M, Chambless L, et al.: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291: 565-575. 10.1001/jama.291.5.565View ArticlePubMedGoogle Scholar
- Bønaa K, Njølstad I, Ueland P, et al.: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354: 1578-1588. 10.1056/NEJMoa055227View ArticlePubMedGoogle Scholar
- Joseph Loscalzo: Homocysteine trials – Clear Outcomes for Complex reasons. N Engl J Med 2006, 354(15):1629-32. 10.1056/NEJMe068060View ArticleGoogle Scholar
- McCully K: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56: 111-28.PubMed CentralPubMedGoogle Scholar
- Keller C, Hoffman U, Loscalzo J: Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vascular Medicine 2002, 7(3):227-239. 10.1191/1358863x02vm428raView ArticlePubMedGoogle Scholar
- Lentz S: Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005, 3(8):1646-54. 10.1111/j.1538-7836.2005.01364.xView ArticlePubMedGoogle Scholar
- Dayal S, Lentz S: Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler Thromb Vasc Biol 2008, 28(9):1596-605. 10.1161/ATVBAHA.108.166421PubMed CentralView ArticlePubMedGoogle Scholar
- Hofmann M, Lalla E, Gleason M, Kohl B, Wolf B, Kiesel W, Stern D, Schmidt A: Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001, 107(6):675-83. 10.1172/JCI10588PubMed CentralView ArticlePubMedGoogle Scholar
- Lange H, Suryapranata H, De Luca G, Börner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH: Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004, 350(26):2673-81. 10.1056/NEJMoa032845View ArticlePubMedGoogle Scholar
- Fernandez C, Yebra M, Ribera C, Toledo T, Martin M, Gomez P: Venous thromboembolism and hyperhomocysteinemia as first manifestation of pernicious anemia. Rev Clin Esp 2005, 205(10):489-92. 10.1157/13079763View ArticleGoogle Scholar
- Limal N, Scheuermaier K, Tazi Z, Sene D, Piette J, Cacoub P: Hyperhomocysteinaemia, thrombosis and pernicious anaemia. Thromb Haemost 2006, 96(2):233-5.PubMedGoogle Scholar
- Küpeli E, Cengiz C, Cila A, Karnak D: Hyperhomocysteinemia due to pernicious anemia leading to pulmonary thromboembolism in a heterozygous mutation carrier. Clin Appl Thromb Hemost 2008, 14(3):365-8. 10.1177/1076029607305101View ArticlePubMedGoogle Scholar
- Rozen R: Genetic modulation of homocysteinemia. Semin Thromb Hemost 2000, 26: 255-261. 10.1055/s-2000-8470View ArticlePubMedGoogle Scholar
- Selhub J, Morris MS, Jaques PF: In vitamin b12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentration. PNAS 2007, 104(50):19995-20000. 10.1073/pnas.0709487104PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.